Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   12/12/2025
54,70 USD (+7,00%)
(+7,00%)   12/12/2025

6 december 2025 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 november 2025 · New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting · Persbericht

6 november 2025 · Nektar Therapeutics Reports Third Quarter 2025 Financial Results · Persbericht

30 oktober 2025 · Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London · Persbericht

28 oktober 2025 · Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets · Persbericht

22 oktober 2025 · Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting · Persbericht

18 september 2025 · Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 · Persbericht

9 september 2025 · Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 · Persbericht

4 september 2025 · Nektar Therapeutics to Participate in Two Investor Conferences in September · Persbericht

7 augustus 2025 · Nektar Therapeutics Reports Second Quarter 2025 Financial Results · Persbericht

1 augustus 2025 · Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets · Persbericht

29 juli 2025 · Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata · Persbericht

2 juli 2025 · Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

1 juli 2025 · Nektar Therapeutics Announces Pricing of $100 Million Public Offering · Persbericht

30 juni 2025 · Nektar Therapeutics Announces Proposed Public Offering · Persbericht

24 juni 2025 · REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis · Persbericht

23 juni 2025 · Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 · Persbericht

13 mei 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference · Persbericht

8 mei 2025 · Nektar Therapeutics Reports First Quarter 2025 Financial Results · Persbericht

2 mei 2025 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets · Persbericht

Mijn selecties